Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics (ATHE) is a development‑stage biopharmaceutical group focused on neurodegenerative diseases, notably ATH434 for Multiple System Atrophy (MSA). The company reported a net loss of A$12.15 million for the year and recorded a A$5.44 million R&D tax incentive as other income. Cash and cash equivalents increased to A$33.16 million at June 30, 2025, supported by significant equity raises including a placement of 3.636 billion shares at A$0.011 and issuance of 1.222 billion listed long‑dated options. Multiple patents (including composition of matter for ATH434) have been granted in several jurisdictions; one U.S. patent lists expiry June 7, 2026. Clinical and conference activity in 2024–2025 includes Phase 2 ATH434 data presented at major neurology meetings. The company continues to disclose material risks: ongoing operating losses, need for further financing, clinical development and manufacturing risks, intellectual property challenges, and NASDAQ listing and PFIC considerations.